Roche Launches State-of-the-Art Institute of Human Biology Facility to Advance Next-Generation Human Model Systems in Drug Discovery and Development
Roche has officially inaugurated a new state-of-the-art research facility to serve as the home of its Institute of Human Biology (IHB), marking a major step forward in its long-term vision to transform drug discovery and development through advanced human-relevant model systems. The new institute is designed to accelerate scientific innovation by combining cutting-edge biological research with emerging technologies, ultimately aiming to improve the speed, accuracy, and success rates of bringing new medicines to patients.
The launch of this new research hub underscores Roche’s commitment to maintaining its position at the forefront of global biomedical innovation, particularly within Switzerland, which continues to serve as a cornerstone of the company’s research and development ecosystem. By investing heavily in infrastructure, talent, and next-generation technologies, Roche is positioning itself to redefine how diseases are studied and how therapies are developed in the modern era.
Thomas Schinecker, Chief Executive Officer of the Roche Group, emphasized the strategic importance of the Institute of Human Biology during the inauguration. He highlighted that the facility represents more than just a physical expansion—it reflects a deeper commitment to advancing scientific capabilities in one of the world’s leading innovation hubs. Roche invests approximately CHF 3.5 billion annually in research activities within Switzerland, and this new institute is expected to play a pivotal role in maximizing the impact of that investment.
According to Schinecker, the integration of human organoid systems with advanced artificial intelligence technologies could fundamentally reshape the pharmaceutical research landscape. By making research and development more predictive, scientists can better anticipate how new treatments will perform in real human systems before entering clinical trials. This not only improves efficiency but also has the potential to significantly reduce development timelines, enabling patients to access innovative therapies faster than ever before.
Leading the Institute of Human Biology is Azad Bonni, who serves as its Global Head and Director. Bonni stressed that the future of medicine depends on the ability to harness sophisticated technologies that go beyond traditional experimental models. He noted that current drug development approaches often rely on systems that fail to fully replicate the complexity of human biology, leading to inefficiencies and high failure rates in later-stage clinical trials.
The Institute of Human Biology seeks to address these limitations by pioneering advanced human model systems capable of closely mimicking real human disease conditions. Through a deeper understanding of disease mechanisms, researchers aim to predict more accurately whether and how potential treatments will work in patients. This shift represents a significant evolution in biomedical research, moving away from conventional models toward more human-centric approaches.
At the core of IHB’s scientific strategy is the integration of multiple disciplines, including human disease biology, computational biology, and translational bioengineering. By bringing together experts from these diverse fields, the institute fosters a highly collaborative environment where multidisciplinary teams can work on complex scientific challenges. This approach enables the development of sophisticated experimental systems that provide unprecedented insights into disease progression and therapeutic response.
Among the innovative technologies being developed and utilized at the institute are organoids—miniature, lab-grown versions of human organs—as well as complex cultured tissue systems and microfluidic “organ-on-chip” platforms. These technologies allow researchers to recreate key aspects of human physiology in controlled laboratory settings. Additionally, in silico modeling, powered by advanced computational tools and artificial intelligence, plays a critical role in simulating biological processes and predicting treatment outcomes.
Together, these advanced systems are helping to deepen the understanding of fundamental disease biology while also transforming how new drugs are discovered and tested. By bridging the gap between basic scientific research and industrial application, the Institute of Human Biology is expected to drive more efficient and effective therapeutic development pipelines.
The new facility, known as Building 92, has been specifically designed to support this ambitious vision. It will accommodate up to 250 researchers and offers a flexible, modular laboratory setup that can evolve alongside scientific needs. The design emphasizes collaboration, with shared spaces and infrastructure that encourage interaction between different scientific disciplines. This environment is intended to foster creativity, accelerate innovation, and enable rapid translation of discoveries into practical applications.
Beyond the institute itself, the inauguration reflects Roche’s broader investment strategy in Switzerland. The company is currently investing approximately CHF 1.4 billion in the development of its Basel and Kaiseraugst sites, further strengthening its presence in the region. Since 2016, Roche has invested around CHF 7 billion in its Swiss infrastructure, alongside an additional CHF 33 billion dedicated to research and development activities within the country.
These investments highlight Roche’s long-standing commitment to Switzerland as a global center for pharmaceutical innovation. Over the past decade, the company’s total investment in the country has reached approximately CHF 41 billion, underscoring its belief in the importance of sustained funding to drive scientific progress and maintain competitive advantage in the rapidly evolving healthcare landscape.
In summary, the inauguration of the Institute of Human Biology’s new research home represents a transformative milestone for Roche. By combining advanced human model systems with artificial intelligence and interdisciplinary collaboration, the company is redefining the future of drug discovery and development. The institute not only enhances Roche’s scientific capabilities but also reinforces its mission to deliver innovative, life-changing treatments to patients worldwide more efficiently and effectively.
About the Institute of Human Biology
Roche’s Institute of Human Biology (IHB), based in Basel, was founded in 2023 and is a global leader in developing and engineering next-generation human model systems, such as advanced tissue cultures, organoids, organoids-on-chips, and in silico modelling to better understand human disease and accelerate the development of new therapeutics and diagnostics.
Human model systems are simple representations of human tissues that also have the potential to reduce reliance on animal testing. The institute leverages its unique setup, multidisciplinary expertise and new state-of-the-art facility in Building 92 to foster innovative collaborations and stay at the forefront of biomedical research. By bridging basic research discovery and industry application, the institute will facilitate the rapid translation of groundbreaking science into patient-focused solutions.
Source Link:https://www.roche.com/
